miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression

Cell Proliferation

Volumn 50, Issue 3, 2017, Pages

  Zhou, Hui ^a,b   Lin, Changwei ^a,c   Zhang, Yi ^a   Zhang, Xiuzhong ^a   Zhang, Chong ^a   Zhang, Pengbo ^a   Xie, Xingwang ^b   Ren, Zeqiang ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b TONGREN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

chemoresistance; colorectal cancer; MDR1 P gp; miR 506

Indexed keywords

BETA CATENIN; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; MESSENGER RNA; MICRORNA; MICRORNA 506; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; UNCLASSIFIED DRUG; WNT PROTEIN; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; MIRN506 MICRORNA, HUMAN; MULTIDRUG RESISTANCE PROTEIN; PLATINUM COMPLEX;

ADULT; AGED; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE EXPRESSION; GENE OVEREXPRESSION; HCT 116 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN SITU HYBRIDIZATION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; MTT ASSAY; OVERALL SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CYCLE; CLINICAL TRIAL (TOPIC); COLORECTAL NEOPLASMS; DEFICIENCY; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; METABOLISM; MIDDLE AGED; TUMOR CELL CULTURE; VERY ELDERLY; WNT SIGNALING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; TUMOR CELLS, CULTURED; WNT SIGNALING PATHWAY;

EID: 85013421177     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/cpr.12341     Document Type: Article

References (35)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
2. Ahmed FE. Molecular markers that predict response to colon cancer therapy. Expert Rev Mol Diagn. 2005;5:353–375.
3. Bhayani MK, Calin GA, Lai SY. Functional relevance of miRNA sequences in human disease. Mutat Res. 2012;731:14–19.
4. Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol. 2013;774:1–20.
5. Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15:272–284.
6. Zhai H, Fesler A, Ju J. MicroRNA: a third dimension in autophagy. Cell Cycle. 2013;12:246–250.
7. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101:2999–3004.
8. Chai H, Liu M, Tian R, Li X, Tang H. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin. 2011;43:217–225.
9. Li PL, Zhang X, Wang LL, et al. MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5. Carcinogenesis. 2015;36:1484–1493.
10. Li J, Chen Y, Zhao J, Kong F, Zhang Y. miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett. 2011;304:52–59.
11. Zhong M, Bian Z, Wu Z. miR-30a suppresses cell migration and invasion through downregulation of PIK3CD in colorectal carcinoma. Cell Physiol Biochem. 2013;31:209–218.
12. Tong JL, Zhang CP, Nie F, et al. MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells. FEBS Lett. 2011;585:3560–3568.
13. Zhou Y, Wan G, Spizzo R, et al. miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol Oncol. 2014;8:83–92.
14. Wan LY, Deng J, Xiang XJ, et al. miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res Commun. 2015;457:125–132.
15. Zhang Z, Ma J, Luan G, et al. MiR-506 suppresses tumor proliferation and invasion by targeting FOXQ1 in nasopharyngeal carcinoma. PLoS ONE. 2015;10:e0122851.
16. Zhang Y, Lin C, Liao G, et al. MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2. Oncotarget. 2015;6:32586–32601.
17. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688–8696.
18. Chen H, Ren C, Han C, Wang D, Chen Y, Fu D. Expression and prognostic value of miR-486-5p in patients with gastric adenocarcinoma. PLoS ONE. 2015;10:e0119384.
19. Liu X, Wang Y, Yin PH, et al. Wnt/β-catenin signal pathway regulates VEGF expression in human colorectal cancer cells. China Oncol. 2012;22:881–885.
20. Shen DY, Zhang W, Zeng X, Liu CQ. Inhibition of Wnt/beta-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma. Cancer Sci. 2013;104:1303–1308.
21. Zhang H, Jing X, Wu X, et al. Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes. Anticancer Drugs. 2015;26:706–715.
22. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000;11:265–283.
23. Montazami N, Kheir Andish M, Majidi J, et al. siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells. Cell Mol Biol. 2015;61:98–103.
24. Liu G, Yang D, Rupaimoole R, et al. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst. 2015;107:djv108.
25. Liu G, Xue F, Zhang W. miR-506: a regulator of chemo-sensitivity through suppression of the RAD51-homologous recombination axis. Chin J Cancer. 2015;34:44.
26. Flahaut M, Meier R, Coulon A, et al. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene. 2009;28:2245–2256.
27. Yang W, Yan HX, Chen L, et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 2008;68:4287–4295.
28. Yamada T, Takaoka AS, Naishiro Y, et al. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res. 2000;60:4761–4766.
29. Stein U, Fleuter C, Siegel F, et al. Impact of mutant beta-catenin on ABCB1 expression and therapy response in colon cancer cells. Br J Cancer. 2012;106:1395–1405.
30. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–337.
31. Shin J, Shin Y, Oh SM, et al. MiR-29b controls fetal mouse neurogenesis by regulating ICAT-mediated Wnt/beta-catenin signaling. Cell Death Dis. 2014;5:e1473.
32. Strillacci A, Valerii MC, Sansone P, et al. Loss of miR-101 expression promotes Wnt/beta-catenin signalling pathway activation and malignancy in colon cancer cells. J Pathol. 2013;229:379–389.
33. Su J, Zhang A, Shi Z, et al. MicroRNA-200a suppresses the Wnt/beta-catenin signaling pathway by interacting with beta-catenin. Int J Oncol. 2012;40:1162–1170.
34. Xu J, Zhu X, Wu L, et al. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/beta-catenin pathway. Liver Int. 2012;32:752–760.
35. Takahashi-Yanaga F. Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol. 2013;86:191–199.